Patents Examined by Hong Liu
  • Patent number: 6610702
    Abstract: The present invention comprises compounds, compositions thereof, and methods capable of delivering inositol hexaphospahte (IHP) to the cytoplasm of mammalian cells. In certain embodiments, the present invention relates to compounds, compositions thereof, and methods that enhance the ability of mammalian red blood cells to deliver oxygen, by delivering IHP to the cytoplasm of the red blood cells.
    Type: Grant
    Filed: August 1, 2001
    Date of Patent: August 26, 2003
    Assignee: GMP Oxycell, Inc.
    Inventors: Jean-Marie Lehn, Yves Claude Nicolau, Stephane P. Vincent
  • Patent number: 6605617
    Abstract: Organic compounds having the formulas I and II are provided where the variables have the values described herein. Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.
    Type: Grant
    Filed: September 11, 2001
    Date of Patent: August 12, 2003
    Assignee: Chiron Corporation
    Inventors: Paul A. Renhowe, Sabina Pecchi, Timothy D. Machajewski, Cynthia M. Shafer, Clarke Taylor, William R. McCrea, Jr., Christopher McBride, Elisa Jazan
  • Patent number: 6605615
    Abstract: Hydrazones and hydrazone analogs are provided which are useful as upregulators of LDL receptors and can be used in the treatment of hypercholesterolemia and related disorders and conditions.
    Type: Grant
    Filed: March 1, 2001
    Date of Patent: August 12, 2003
    Assignee: Tularik Inc.
    Inventors: Julio C. Medina, Hirohiko Hasegawa
  • Patent number: 6602867
    Abstract: Triazole compounds of the following formula where R1, R2, A and B have the meanings given in the description are described. The compounds according to the invention possess a high affinity for the dopamine D3 receptor and can therefore be used for treating diseases which respond to the influence of dopamine D3 ligands.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: August 5, 2003
    Assignee: Abbott Laboratories
    Inventors: Dorothea Starck, Hans-Jörg Treiber, Liliane Unger, Barbara Neumann-Schultz, Kai Blumbach, Dietmar Schöbel
  • Patent number: 6599910
    Abstract: Novel substitued triazole compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.
    Type: Grant
    Filed: June 11, 2001
    Date of Patent: July 29, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: Jerry L. Adams, Dennis Lee
  • Patent number: 6593324
    Abstract: A compound of formula I, wherein A, Ra, Rb, R1 to R5, m and t are as defined as disclosed, or a pharmaceutically acceptable salt or ester thereof, useful as an alpha-2 antagonist. The compounds I can be used for the treatment of diseases or conditions where alpha-2 antagonists are indicated to be effective.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: July 15, 2003
    Assignees: Orion Corporation, Oy Juvantia Pharma Ltd.
    Inventors: Siegfried Wurster, Mia Engström, Juha-Matti Savola, Iisa Höglund, Jukka Sallinen, Antti Haapalinna, Andrei Yurievitch Tauber, Anna-Marja Katariina Hoffrén, Harri Elias Salo
  • Patent number: 6593322
    Abstract: Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-&bgr; over ER-&agr;. Methods are disclosed for modulating ER-&bgr; in cell and/or tissues expressing the same, including cells and/or tissue that preferentially ER-&bgr;. Methods for treating estrogen-related conditions are also disclosed, including conditions such as is breast cancer, testicular cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, urinary incontinence, hairloss, cataracts, natureal hormonal imbalances, and adverse reproductive effects associated with exposure to environmental chemicals.
    Type: Grant
    Filed: September 21, 2000
    Date of Patent: July 15, 2003
    Assignee: Signal Pharmaceuticals, Inc.
    Inventors: Shripad S. Bhagwat, Leah Marie Gayo-Fung, Bernd M. Stein, Qi Chao, Anthony R. Gangloff, Jeffrey A. McKie, Kenneth D. Rice
  • Patent number: 6589959
    Abstract: The present invention relates to a crystalline form of the compound bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid]calcium salt, as well as processes for its manufacture and pharmaceutical compositions comprising the crystalline form, which is useful as an agent for treating hyperlipidemia, hypercholesterolemia and atherosclerosis.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: July 8, 2003
    Assignee: Astrazeneca AB
    Inventor: Nigel P Taylor
  • Patent number: 6589953
    Abstract: The invention concerns novel indole piperazine derivatives of formula (I). It also concerns a method for preparing said compounds and their use as therapeutically active substances, in particular for treating or preventing diseases related to the disfunction of 5-HT1-like receptors.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: July 8, 2003
    Assignee: Pierre Fabre Medicament
    Inventors: Michel Perez, Serge Halazy
  • Patent number: 6586437
    Abstract: Treatment of psychoses with (S)-hydroxynefazodone is disclosed.
    Type: Grant
    Filed: November 14, 2001
    Date of Patent: July 1, 2003
    Assignee: Sepracor Inc.
    Inventors: Mark G. Currie, Thomas P. Jerussi, Paul D. Rubin
  • Patent number: 6586423
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: February 1, 2002
    Date of Patent: July 1, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, George D. Hartman, Peter J. Manley, Randall W. Hungate, Leonard Rodman
  • Patent number: 6586446
    Abstract: The present application describes modulators of CCR3 of formula (I): A—E—NR1—G  (I) or pharmaceutically acceptable salt forms thereof, useful for the prevention of inflammatory diseases such as asthma and other allergic diseases.
    Type: Grant
    Filed: October 13, 2000
    Date of Patent: July 1, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: John V Duncia, Joseph B Santella, III, Daniel S Gardner, Dean A Wacker
  • Patent number: 6586424
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: February 1, 2002
    Date of Patent: July 1, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, George D. Hartman, Peter J. Manley
  • Patent number: 6583141
    Abstract: The present invention is concerned with the compounds of formula wherein m, n and p are each independently 0 or 1 and q is 0, 1, 2, 3, 4 or 5; —A1═A2—A3═A4— is a pyridinylidene, pyridazinylidene, pyrimidinylidene, pyrazinylidene or phenylidene; B represents an amide, ketone or oxadiazole; D represents Ar or Het; Q represents a covalent direct bond or a ketone, —N—, —O—, —CR5R6—, amide ethenyl, imine, sulfonyl, sulfinyl, 3-oxobutenyl, pyrazole, isoxazole or thiazole; L represents Ar or Het; R1 represents hydrogen, halo, hydroxy, C(2-6)alkenyl, C(2-6)alkynyl, C(3-6)cycloalkyl, C(3-6)cycloalkenyl, cyano, guanidine, nitro, NR17R18, an optionally substituted C(1-6)alkyl or C(1-6)alkyloxy; R2 and R3 each independently represent hydrogen, halo, C(1-6)alkyloxy or an optionally substituted C(1-6)alkyl; R5 and R6 each independently represent hydrogen, hydroxy, halo, an optionally substituted C(1-6)alkyl, C(2-6)alkenyl, C(2-6)alkynyl, C(3-
    Type: Grant
    Filed: April 6, 2001
    Date of Patent: June 24, 2003
    Assignee: Janssen Pharmaceutica, N.V.
    Inventors: Eddy Jean Edgard Freyne, José Ignacio Andrés-Gil, Frederik Dirk Deroose, Davy Petrus Franciscus Maria Petit, Maria Encarnacion Matesanz-Ballesteros, Rosa Maria Alvarez Escobar
  • Patent number: 6583166
    Abstract: The invention relates to triazole compounds of formula (I), in which R1, R2, A and B have the meanings given in the description. The compounds provided for in the invention have a high affinity for the dopamine-D3-receptor and can therefore be used for the treatment of diseases which respond to the influence of dopamine-D3-ligands.
    Type: Grant
    Filed: July 16, 2001
    Date of Patent: June 24, 2003
    Assignee: Abbott Laboratories
    Inventors: Dorothea Starck, Hans-Jörg Treiber, Liliane Unger, Barbara Neumann-Schultz, Kai Blumbach, Dietmar Schöbel
  • Patent number: 6583147
    Abstract: The present invention relates to pyrazolopyrimidinone derivatives of formula 1, their preparation method and pharmaceutical compositions containing the said derivatives. The compounds have efficacy on the treatment of impotence, one of male sexual dysfunctions with the side effects reduced.
    Type: Grant
    Filed: May 9, 2001
    Date of Patent: June 24, 2003
    Assignee: Dong A Pharm Co., Ltd.
    Inventors: Moohi Yoo, Wonbae Kim, Min Sun Chang, Joong In Lim, Dong Sung Kim, Ik Yon Kim, Tae Kyun Lim, Byoung Ok Ahn, Kyung Koo Kang, Miwon Son, Hyounmie Doh, Soonhoe Kim, Hyunjoo Shim, Taeyoung Oh, Heungjae Kim, Dong Goo Kim
  • Patent number: 6579892
    Abstract: Triazole compounds of the following formula where R1, R2, A and B have the meanings given in the description are described. The compounds according to the invention possess a high affinity for the dopamine D3 receptor and can therefore be used for treating diseases which respond to the influence of dopamine D3 ligands.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: June 17, 2003
    Assignee: Abbott Laboratories
    Inventors: Dorothea Starck, Hans-Jörg Treiber, Liliane Unger, Barbara Neumann-Schultz, Kai Blumbach, Dietmar Schöbel
  • Patent number: 6576632
    Abstract: The present invention relates to compounds of formula I and to pharmaceutically acceptable salts, hydrates and prodrugs thereof, wherein R1, R2, R3, R4, R5, R10, R11, b, m, n, p and v are as defined herein. The invention also relates to pharmaceutical compositions containing the above compounds and methods of treating hyperproliferative disorders in mammals by administering the above compounds.
    Type: Grant
    Filed: April 13, 2000
    Date of Patent: June 10, 2003
    Assignee: Pfizer Inc
    Inventors: Steven W. Goldstein, Kelly P. Longo, James F. Blake, Mohamed M. A. Awad, Kenneth P. Raiche, Kevin W. Kramer
  • Patent number: 6573275
    Abstract: A compound of formula (I): wherein R1 represents a group of formula (A) where each of W, X, Y and Z and Z represents either a group CR or the nitrogen atom, provided that not more than two of W, X, Y and Z represent the nitrogen atom and where each R present is independently selected from hydrogen and halogen atoms and cyano, amino, hydrazino, acylamino, hydroxy, alkyl, hydroxyalkyl, alkoxy, haloalkyl, haloalkoxy, alkenyl, alkenyloxy, alkoxyalkenyl, alkynyl, carboxylic acyl, alkoxycarbonyl, aryl and heterocyclyl groups, said groups comprising up to 6 carbon atoms, and wherein R2 represents hydrogen or cyano or a group selected from alkyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, alkenyl, aralkenyl, alkynyl, alkoxycarbonyl, alkanesulfonyl, arenesulfonyl, alkanyloxycarbonyl, aralkyloxycarbonyl, aryloxycarbonyl, heterocyclylalkyl, carbamyl or dithiocarboxyl groups, said groups comprising from 1 to 15 carbon atoms, said groups being optionally substituted with one or more substituents selecte
    Type: Grant
    Filed: April 12, 2002
    Date of Patent: June 3, 2003
    Assignee: Syngenta Limited
    Inventors: Christopher John Urch, Roger Salmon, Terence Lewis, Christopher Richard Ayles Godfrey, Martin Stephen Clough
  • Patent number: 6566373
    Abstract: The invention relates to 3-hydroxy-and 3-keto-cyclohetero-substituted leucine compounds that are inhibitors of cysteine proteases, particularly cathepsin K, and are useful in the treatment of diseases in which inhibition of bone loss is a factor. The 3-hydroxy-or 3-keto-moiety is bonded to a tetrahydrothiophene, tetrahydrothiopyran, tetrahydrofuran or tetrahydropyran ring.
    Type: Grant
    Filed: July 30, 2001
    Date of Patent: May 20, 2003
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.
    Inventors: Andrew D Gribble, Ashley Edward Fenwick, Robert W Marquis, Daniel F Veber, Jason Witherington